Dominari (NASDAQ:DOMH) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Dominari (NASDAQ:DOMH) from a hold rating to a sell rating in a research report report published on Saturday.

Separately, Weiss Ratings lowered shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Dominari Stock Down 0.7%

Shares of NASDAQ DOMH opened at $2.92 on Friday. The firm’s 50-day moving average price is $3.11 and its two-hundred day moving average price is $4.23. Dominari has a 52-week low of $2.68 and a 52-week high of $8.40. The stock has a market capitalization of $66.03 million, a P/E ratio of -0.75 and a beta of 0.80.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DOMH. Creek Drive Management Group LLC acquired a new position in Dominari in the fourth quarter worth approximately $1,861,000. Two Sigma Investments LP acquired a new position in Dominari in the third quarter worth approximately $771,000. Renaissance Technologies LLC acquired a new position in Dominari in the fourth quarter worth approximately $412,000. Connective Capital Management LLC grew its position in Dominari by 26.2% in the third quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after buying an additional 69,545 shares during the last quarter. Finally, Susquehanna Advisors Group Inc. acquired a new position in Dominari in the fourth quarter worth approximately $182,000. Institutional investors and hedge funds own 42.48% of the company’s stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.